RHHVF
July 25, 2024 - AI Summary
Undervalued by 137.1% based on the discounted cash flow analysis.
Market cap | $258.69 Billion |
---|---|
Enterprise Value | $291.53 Billion |
Dividend Yield | $11.012 (3.74084072502892%) |
Earnings per Share | $10.32 |
Beta | 0.17 |
Outstanding Shares | 802,307,692 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 24.92 |
---|---|
PEG | -46.4 |
Price to Sales | 2.47 |
Price to Book Ratio | 7.18 |
Enterprise Value to Revenue | 2.77 |
Enterprise Value to EBIT | 13.03 |
Enterprise Value to Net Income | 19 |
Total Debt to Enterprise | 0.14 |
Debt to Equity | 1.25 |
No data
No data
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ...